Stockscreener 앱 받기
3.65
1.88%
-0.07
시장 영업 전:
3.63
-0.02
-0.55%
전일 마감가:
$3.72
열려 있는:
$3.7
하루 거래량:
1.09M
Relative Volume:
0.77
시가총액:
$1.25B
수익:
$787.89M
순이익/손실:
$20.56M
주가수익비율:
62.39
EPS:
0.0585
순현금흐름:
$96.54M
1주 성능:
-3.95%
1개월 성능:
+16.24%
6개월 성능:
+53.36%
1년 성능:
-28.71%
1일 변동 폭
$3.645
$3.79
1주일 범위
$3.54
$3.81
52주 변동 폭
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, TXG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.65 | 1.27B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
242.75 | 38.72B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
59.50 | 11.95B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
49.36 | 9.32B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
102.79 | 8.56B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
55.63 | 7.56B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
Technology Crossover Management X Ltd. Buys Shares of 1,653,566 GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) Q2 2026 Earnings Call Transcript - AOL.com
GoodRx Holdings Inc (GDRX) (Q2 2026) Earnings Call Highlights: R - GuruFocus
GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen - MarketBeat
Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX) - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
GDRX Maintained by UBS -- Price Target Raised to $3.75 - GuruFocus
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook - Yahoo Finance
GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise - Yahoo Finance
GOODRX HOLDINGS, INC. : UBS RAISES TARGET PRICE TO $3.75 FROM $2.5 - Bitget
GoodRx (NASDAQ:GDRX) Trading Down 5.1%What's Next? - MarketBeat
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope (NASDAQ:GDRX) - Seeking Alpha
Why Is GoodRx Holdings (GDRX) Putting Finance And Strategy Under Justin Fengler? - Sahm
GDRX Maintained by Citigroup -- Price Target Raised to $5.00 - GuruFocus
GoodRx (NASDAQ:GDRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
GDRX Maintained by TD Cowen -- Price Target Raised to $5.00 - GuruFocus
GDRX Q2 Deep Dive: Pharma Direct and Subscription Growth Drive Upgraded Outlook - finance.yahoo.com
GOODRX HOLDINGS, INC. : CITIGROUP RAISES TARGET PRICE TO $5 FROM $4 - Bitget
GDRX Maintains Overweight by Wells Fargo -- Price Target Raised to $5.00 - GuruFocus
GoodRx Holdings Price Target Raised to $5.00/Share From $3.50 by Wells Fargo - Moomoo
Prescription savings giant GoodRx could be opening office at The Pearl - The Business Journals
GoodRx Holdings Inc (GDRX) Stock Analysis & Forecast - tradingkey.com
GoodRx Holdings Inc (GDRX) Stock News Today - tradingkey.com
Wells Fargo & Company Boosts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - MarketBeat
GoodRx Holdings Inc (GDRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.7 - tradingview.com
Morgan Stanley Adjusts Price Target on GoodRx to $4 From $3, Maintains Equalweight Rating - marketscreener.com
Earnings call transcript: GoodRx lifts 2026 outlook after Q2 revenue beat - Investing.com Canada
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.55, Implies 9% Upside - TradingView
Transcript : GoodRx Holdings, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
GoodRx Lets Customers Shop Where They Want, CEO Says - marketscreener.com
GoodRx Q2 Earnings Call Highlights - MarketBeat
GoodRx (NASDAQ:GDRX) Stock Price Up 15.7%Here's Why - MarketBeat
GDRX: Pharma Direct and subscriptions drove Q2 outperformance, leading to raised 2026 guidance - TradingView
GoodRx Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
GDRX Looks 42.2% Undervalued on GF Value™ - GuruFocus
GDRX SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
GoodRx (NASDAQ:GDRX) Posts Earnings Results, Hits Estimates - MarketBeat
GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates - Yahoo Finance
GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Tranche Update on GoodRx Holdings, Inc.'s Equity Buyback Plan announced on February 29, 2024. - marketscreener.com
Is GoodRx Holdings Inc (GDRX) Undervalued After Q2 Earnings? EPS - GuruFocus
GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars - Barchart.com
GoodRx Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aug 05 (Reuters)GoodRx Holdings Q2 Revenue - Moomoo
GDRX: Pharma Direct and subscription growth drove raised 2026 guidance despite lower transactions - tradingview.com
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q2 EPS; Offers Guidance - StreetInsider
GoodRx Reports Second Quarter 2026 Results - marketscreener.com
GoodRx Holdings, Inc. 2026: Revenue $200.41M, EPS $0.02— 10-Q Summary - TradingView
GoodRx Holdings (NASDAQ: GDRX) elevates Justin Fengler to CFO role - stocktitan.net
GoodRx Holdings (NASDAQ: GDRX) pivots as Rx revenue falls 26% - Stock Titan
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Goodrx Holdings Inc 주식 (GDRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
0.09%
1.46%
자본화:
|
볼륨(24시간):